26 October 2022 in Science Translational Medicine
Dengue virus (DENV) infections are major causes of morbidity and mortality throughout the tropics and subtropics. More than 400 million infections are estimated to occur every year, resulting in nearly 100 million symptomatic infections and more than 20,000 deaths. Early immune response kinetics to infection remain unclear, in large part due to the variable incubation period exhibited by the DENVs after introduction into a susceptible host. To fill this knowledge gap, we performed a comprehensive virologic and immunologic analysis of individuals experimentally infected with the underattenuated DENV-1 strain 45AZ5. This analysis captured both the kinetics and composition of the innate, humoral, and cellular immune responses elicited by experimental DENV-1 infection, as well as virologic and clinical features. We observed a robust DENV-specific immunoglobulin A (IgA) antibody response that manifested between the appearance of DENV-specific IgM and IgG in all challenged individuals, as well as the presence of a non-neutralizing/NS1-specific antibody response that was delayed relative to the appearance of DENV virion–specific humoral immunity. RNA sequencing analysis revealed discrete and temporally restricted gene modules that correlated with acute viremia and the induction of adaptive immunity. Our analysis provides a detailed description, in time and space, of the evolving matrix of DENV-elicited human inflammation and immunity and reveals several previously unappreciated immunological aspects of primary DENV-1 infection that can inform countermeasure development and evaluation.
1 April 2024 in Nature Microbiology
7 June 2026 in The Journal of Immunology
Despite an effective vaccine against the hepatitis B virus (HBV), there are about 250 million people living with chronic HBV (CHB) worldwide and one million deaths annually. Most children and about 5% of adults exposed to HBV will fail to clear the virus, developing a lifelong infection. Hepatitis B surface antigen (HBsAg)-specific antibody (HBsAb) is protective in uninfected individuals and is considered a component of a functional cure. Immune factors that play important roles in regulating inflammation, such as TGF-β, IL-10, and regulatory T cells (Tregs), may also contribute to CHB pathogenesis. However, the early regulatory factors that promote HBsAg seroconversion are not well understood. To address this, we utilized adeno-associated virus (AAV)-mediated delivery of HBV (AAV-HBV) to mice. In this model, C57BL/6 mice fail to develop effective HBsAb responses, while BALB/c mice more efficiently seroconvert HBsAg. While inhibiting TGF-β, IL-10, or Tregs did not impact serum HBsAg levels in C57BL/6 mice, TGF-β depletion in BALB/c mice ablated the humoral response to HBsAg. Neutralizing IL-10, blocking CTLA-4, or depleting Tregs alone did not affect the HBsAb response in BALB/c mice. However, Treg depletion in the absence of TGF-β restored HBsAg clearance in an IL-10- and CTLA-4-independent manner. These findings highlight the immune balance regulated by TGF-β in the early adaptive response to an HBV antigen, as well as context-dependent compensatory interactions that may directly or indirectly impact antigen-specific humoral immunity.